|Awarded On||March 29, 2012|
|Title||Eliminating Cancer Pain by Growth Factor Inhibition|
|Award Mechanism||Bridging the Gap: Early Translational Research Awards|
|Institution/Organization||The University of Texas M.D. Anderson Cancer Center|
|Principal Investigator/Program Director||Howard Gutstein|
|Cancer Sites||All Sites|
One of the most feared complications of cancer is unbearable, unrelenting pain. The prevalence of pain in patients presenting with cancer or undergoing treatment is greater than 50%, while the prevalence of chronic pain in cancer survivors has been estimated at 33%. Opiate narcotics, which have been used for centuries, are still the primary treatment for severe cancer pain. Unfortunately, narcotics are not very effective against pain caused by nerve injury, invasion or compression, which are prominent components of cancer pain. Opiates also become less effective over time because tolerance develops to their pain-relieving effects. For years, narcotic tolerance and cancer pain have long been ...